Navigation Links
River Vision Announces Completion of $17 million Series A Financing
Date:12/12/2012

NEW YORK, Dec. 12, 2012 /PRNewswire-iReach/ -- River Vision Development Corp. today announced the completion of a Series A financing, raising $17 million for the development of a novel protein therapy, RV 001, for the treatment of Graves' Orbitopathy (GO). 

GO is a condition afflicting a proportion of Graves' Disease patients, in which an autoimmune response is mounted against tissues behind the eye, causing inflammation, tissue proliferation and excess production of extracellular matrix.  The resulting excess tissue in the area behind the eye causes the eyeballs to protrude from the socket, resulting in often serious ocular morbidity and significant changes in the patient's appearance.

The Series A financing was led by SR One and Lundbeckfond Ventures with participation from Narrow River Management.  As a result of the financing, Brian M. Gallagher, Jr., Ph.D. a partner at SR One and Johan Kördel, Ph.D. a senior partner at Lundbeckfonden have joined River Vision's Board of Directors. "We are delighted to be working with SR One and Lundbeckfonden on this exciting project," said Dave Madden, CEO of River Vision.  "They bring a wealth of experience and relationships that should be invaluable to River Vision as we bring RV001 forward through development."

"The experience of the management team, the quality of the science behind the hypothesis and unmet medical need in GO combine to make this a very promising rare disease product opportunity" remarked Dr. Gallagher.  "We are pleased to collaborate with SR One and the River Vision management team on this exciting project" added Dr. Kördel "and believe the planned study will give us an excellent read on the potential of RV001 to treat this serious autoimmune condition."

About River Vision Development Corp.

River Vision Development Corp. was founded by Narrow River Management, LP (Narrow River) for the sole purpose of developing RV001 for GO and other potential indications.  The Company is managed under contract with Narrow River, which founds and provides leadership expertise for special purpose drug development companies. 

About SR One

SR One is the independent corporate venture capital arm of GlaxoSmithKline. The firm invests globally in emerging life science companies that are pursuing innovative science which will significantly impact medical care. Since 1985, SR One has invested approximately $700 million in more than 140 companies, and its current portfolio includes over 30 private and public companies. For more information, visit www.srone.com.

About Lundbeckfond Ventures

Lundbeckfond Ventures is an evergreen life science venture fund established and wholly owned by the Lundbeck Foundation. The firm is investing internationally with focus on life science companies that address areas with real unmet medical needs. On an annual basis, Lundbeckfond Ventures invests up to € 50 million. For more information, visit www.lundbeckfondventures.dk

Media Contact: Dave Madden River Vision Development Corp., (212) 582-8400 x105, dmadden@narrowrivermgmt.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE River Vision Development Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. First Paralyzed Formula Race Car Drivers "Road to Indy" Sponsored By Coloplast
2. Safe Driving Prescription for Senior Drivers
3. Nedbank Golf Challenge a Driver for Breast Cancer in South Africa
4. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
5. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
6. Rural Health-Systems Benefit From Remote Pharmacy Technician Supervision
7. Medical Alarm Begins Revenue Recognition from Largest Set of Orders -- Releases New Television Commercial
8. Ted Pacha Joins Pinnaclife as President of its Healthcare Distribution Division
9. DataMotion Files Provisional Patent for Technology that Enables Easy and Secure Doctor-Patient Email Interaction
10. Spot Vision Screener wins Bronze in International Design Excellence Awards
11. Transitions Optical Brings Importance Of Healthy, Enhanced Vision Into Focus By Taking National Sightseeing City Tour To Chicago And Announcing The Citys Top 10 Sights To See
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... STOCKHOLM , Sept. 7, 2017 NuvoAir ... Air Smart Spirometer, announced today a partnership with Novartis Pharma ... partnership solidifies NuvoAir,s position as the leading mobile spirometry platform ... respiratory patients. ... spirometry test ...
(Date:9/6/2017)... , Sept. 6, 2017  Robert G. Szewc, ... Pinnacle Professional Member in recognition of his contributions to ... serves as a Nephrologist at the practice of Kidney ... medicine, kidney care and hypertension solutions. He has worked ... years of career experience, as well as expertise in ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
Breaking Medicine Technology:
(Date:9/21/2017)... CO (PRWEB) , ... September 21, 2017 , ... ... Interview of the Month, Lewis and Clark College Emeritus Professor of Education Gregory ... Faith Boninger, co-author of Asleep at the Switch: Schoolhouse Commercialism, Privacy, and ...
(Date:9/20/2017)... ... September 20, 2017 , ... On ... Best Places to Work in the Research Triangle for 2017. , Winners were ... company had to meet a threshold in employee participation--a percentage that varies based ...
(Date:9/20/2017)... ... September 20, 2017 , ... Mirror Mirror Beauty ... , Look Awesome This Autumn with CoolSculpting®. Scheduled for Thursday, September 28th, the ... , Mirror Mirror Beauty Boutique is Houston’s largest CoolSculpting provider, holding ...
(Date:9/20/2017)... ... September 20, 2017 , ... Compliancy Group is proud ... The Guard®, has helped another long-time client pass their Department of Health and ... the law. , Thanks to the help of the Compliancy Group's Audit Response ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... Five consumer ... innovation and market impact in 27 different categories. Nopavera Plus was named ... category will be announced at SupplySide West 2017 during presentations at SupplySide Central on ...
Breaking Medicine News(10 mins):